GTP

Guanosine triphosphate (GTP) is a purine nucleoside triphosphate. It is one of the building blocks needed for the synthesis of RNA during the transcription process. Its structure is similar to that of the guanine nucleobase, the only difference being that GTP has three phosphate groups, instead of one.

GTP also has the role of a source of energy or an activator of substrates in metabolic reactions, like that of ATP, but more specifically, it is used as a source of energy for protein synthesis. GTP is essential to signal transduction, particularly with G-proteins, as they use GTP binding and hydrolysis as a molecular 'on/off' switch.

Structure and properties

GTP is a nucleoside triphosphate, which means that it consists of three components: a nitrogenous base, a five-carbon sugar, and three phosphate groups. The nitrogenous base is guanine, a purine base with a double-ring structure. The five-carbon sugar is ribose. The three phosphate groups are attached to the sugar molecule at the 5' position, and they are responsible for the molecule's ability to store and transfer energy.

Role in metabolism

In metabolism, GTP is classified as a high-energy molecule. It can donate one of its phosphate groups to another molecule in a process called phosphorylation. This process is important in many metabolic reactions, as it can activate or deactivate enzymes, change the structure of proteins, and drive the synthesis of proteins and nucleic acids.

Role in signal transduction

GTP is also involved in signal transduction pathways. It acts as a molecular 'on/off' switch in these pathways. When GTP is bound to a protein, the protein is 'on' and can transmit a signal. When the GTP is hydrolyzed to GDP (guanosine diphosphate), the protein is 'off' and the signal transmission stops.

See also

• Guanosine diphosphate
• Guanosine monophosphate
• Signal transduction
• G-protein
• Phosphorylation

GTP Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.